Age: 74.0
Sex: M
Vaccine: HEP, HEP, HEP
Symptoms: Inappropriate schedule of product administration, Underdose
Clinical narrative: patient received 20mcg on the 3rd dose of engerix B instead of 40 mcg; patient received 3rd dose of Engerix B on 29 April but was due 14 May; Elderly patient received 4 doses schedule of Engerix B (dose 3); Elderly patient received 4 doses schedule of Engerix B (dose 2); Elderly patient received 4 doses schedule of Engerix B (dose 1); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 74-year-old male patient who received HBV (Engerix B adult) (batch number YY37B, expiry date AUG-2024) for prophylaxis.   Co-suspect products included HBV (Engerix B adult) for prophylaxis and HBV (Engerix B adult) for prophylaxis.   Concurrent medical conditions included hemodialysis (was on hemodialysis ).   On 29-APR-2024, the patient received the 3rd dose of Engerix B adult 20 µg. On 14-MAR-2024, the patient received the 2nd dose of Engerix B adult 40 µg. On 14-FEB-2024, the patient received the 1st dose of Engerix B adult 40 µg. On 14-FEB-2024, not applicable after receiving Engerix B adult and Engerix B adult and an unknown time after receiving Engerix B adult, the patient experienced inappropriate age at vaccine administration (Verbatim: Elderly patient received 4 doses schedule of Engerix B (dose 1)). On 14-MAR-2024, the patient experienced inappropriate age at vaccine administration (Verbatim: Elderly patient received 4 doses schedule of Engerix B (dose 2)). On 29-APR-2024, the patient experienced inappropriate dose of vaccine administered (Verbatim: patient received 20mcg on the 3rd dose of engerix B instead of 40 mcg), drug dose administration interval too long (Verbatim: patient received 3rd dose of Engerix B on 29 April but was due 14 May) and inappropriate age at vaccine administration (Verbatim: Elderly patient received 4 doses schedule of Engerix B (dose 3)). The outcome of the inappropriate dose of vaccine administered, drug dose administration interval too long, inappropriate age at vaccine administration, inappropriate age at vaccine administration and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 08-MAY-2024 and 09-MAY-2024 A pharmacist reported that he/she had a patient who received only 20mcg on the 3rd of 4 doses in the Engerix series which led to inappropriate dose of vaccine administered.  Elderly patient received 4 doses of an adult hemodialysis schedule, which led to inappropriate age at vaccine administration. The patient received 3rd dose of Engerix B earlier than the recommended interval, which led to shortening the vaccine schedule. The reporter wanted to know what the guidance for this was half dose'. The reporter attempted to confirm the dosing was for an adult hemodialysis patient on the 4-dose schedule but the reporter disconnected the chat before providing any additional information.  The vaccine administration facility was the same as primary reporter. Unknown if follow up was permissible and also unknown if the mailing address was correct in reporter's profile.